Determination prostate specific antigen and testosterone in tumour cell lines with encore zinc and sarcosine as well as in prostate cancer patients

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	CERNEI Natalia Vladimirovna MASAŘÍK Michal GUMULEC Jaromír ZÍTKA Ondřej SOCHOR Jiří BABULA Petr KIZEK René
Year of publication	2011
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Tumour markers are biochemical indicators of malignant tumour proliferation. They serve not only for diagnostics of malignant tumour diseases, but also for monitoring of effect of therapy and recurrence of disease. One of the most important indicators of quality of oncological markers is their sensitivity; it means the possibility to detect diseases at the early stages, and specificity to given type of tumour. In the case of prostate carcinoma, prostatic acid phosphatase (PAP) was usually used in the past. PAP was replaced at the end of eighties of last century by serum prostate specific antigen (PSA), which belongs to a group of the best tumour markers, currently available.
Related projects:	Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu